Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)
A Phase 1 Study of Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Sponsor: Gilead Sciences
Listed as NCT05169944, this PHASE1 trial focuses on Brain Cancer and Brain Tumor Adult and remains completed. Sponsored by Gilead Sciences, it has been updated 13 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE1
-
Nov 2024 — Aug 2025 [monthly]
Completed PHASE1
Status: Suspended → Completed
-
Sep 2024 — Nov 2024 [monthly]
Suspended PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
▶ Show 8 earlier versions
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Apr 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .